CHI Logo

 

Overview
Table of Contents
Order
Additional Reports 

Oncology Partnering Terms and Agreements Cover
Download Brochure 

Publication Date: 
February 2012

Page Count: 1,923

Price:
$2,995 Single User
$4,495 Multiple User
$8,995 Single Site
$14,975 Global License

Oncology Partnering Terms & Agreements - Overview

 

Summary 

Oncology Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to oncology trends and structure of deals entered into by leading companies worldwide.

Oncology Partnering Terms and Agreements includes:

  • Trends in oncology dealmaking in the biopharma industry since 2007
  • Analysis of oncology deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life oncology deals
  • Access to over 2,700 oncology contract documents
  • The leading oncology deals by value since 2007
  • Most active oncology dealmakers since 2007
  • The leading oncology partnering resources

 

> Download Brochure 

Description 

The Oncology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the oncology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors oncology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 2,700 links to online copies of actual oncology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in oncology dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading oncology deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of oncology partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), technology type and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in oncology partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of oncology technologies and products.

Key benefits 

Oncology Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of oncology deal trends since 2007
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 2,700 actual oncology contracts entered into by the world’s biopharma companies
  • Detailed access to actual oncology contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a oncology agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

In Oncology Partnering Terms and Agreements, the available contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

By Series:
By Region: